Literature DB >> 3916943

High field 1H-NMR analysis of the 1:1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGpCpG)].

J W Lown1, C C Hanstock.   

Abstract

Complete 1H-nmr assignment has been achieved of the stoichiometric 1:1 complex of the antitumor agent mitoxantrone with the duplex oligomer [d(CpGpCpG)]2. The techniques used included 2D-COSY, 1D-NOE and 2D-HH-INADEQUATE. Comparisons of 1H and 13C chemical shift changes upon addition of drug suggest symmetrical intercalative binding to the center of the tetramer. NOE difference measurements and 31P studies suggest binding of the terminal OH groups of the side chains to the central phosphate groups such that the methylene groups are proximate to C(3)6, C(3)6 and G(4)8 base protons all in the major groove. The data suggest that the side chains bind to the neighboring base pairs from the intercalation site. This is in accord with independent evidence of G,C base preference for binding from spectroscopic and electron microscopy studies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3916943     DOI: 10.1080/07391102.1985.10507626

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  11 in total

1.  A theoretical investigation of the base sequence preferences of monointercalating polymethylene carboxamide derivatives 9-aminoacridine.

Authors:  C Coulombeau; N Gresh
Journal:  Nucleic Acids Res       Date:  1990-02-25       Impact factor: 16.971

2.  A theoretical investigation on the sequence selective binding of mitoxantrone to double-stranded tetranucleotides.

Authors:  K X Chen; N Gresh; B Pullman
Journal:  Nucleic Acids Res       Date:  1986-05-12       Impact factor: 16.971

3.  Employing a ZTP Riboswitch to Detect Bacterial Folate Biosynthesis Inhibitors in a Small Molecule High-Throughput Screen.

Authors:  Kevin R Perkins; Ruben M Atilho; Michelle H Moon; Ronald R Breaker
Journal:  ACS Chem Biol       Date:  2019-11-14       Impact factor: 5.100

4.  DNA sequence specificity of mitoxantrone.

Authors:  C Panousis; D R Phillips
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

5.  A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.

Authors:  Guohua An; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-27       Impact factor: 4.009

Review 6.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 7.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

8.  Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA.

Authors:  Yang Liu; Eleanor Peacey; John Dickson; Christine P Donahue; Suxin Zheng; Gabriele Varani; Michael S Wolfe
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

Review 9.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

10.  Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors.

Authors:  C H Freudenreich; K N Kreuzer
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.